Key points are not available for this paper at this time.
In a post hoc analysis of the phase 2b study, compared with placebo, ensitrelvir demonstrated a reduced time to resolution of 5 symptoms in patients with mild-to-moderate COVID-19. Through this study, we intend to validate and establish the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19.
Yotsuyanagi et al. (Wed,) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: